We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

34 hedge funds and large institutions have $3.36M invested in AIM ImmunoTech in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 36 → 34 (-2)

28% less capital invested

Capital invested by funds: $4.68M → $3.36M (-$1.32M)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
34
Holders Change
-2
Holders Change %
-5.56%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$20.6K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$6.93K
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.15K
4
UBS Group
UBS Group
Switzerland
+$560
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$350

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$141K
2
TSS
Two Sigma Securities
New York
-$24K
3
VF
Virtu Financial
New York
-$10.4K
4
Jane Street
Jane Street
New York
-$8K
5
Wells Fargo
Wells Fargo
California
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.16M – – –
Morgan Stanley
2
Morgan Stanley
New York
$814K -$141K -2,011 -13%
BlackRock
3
BlackRock
New York
$473K -$2.24K -32 -0.4%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$222K – – –
State Street
5
State Street
Massachusetts
$101K – – –
Verition Fund Management
6
Verition Fund Management
Connecticut
$89K – – –
BCM
7
Bridgeway Capital Management
Texas
$88K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$73K +$3.15K +45 +4%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$68K -$770 -11 -0.9%
Northern Trust
10
Northern Trust
Illinois
$50K -$1.54K -22 -2%
Cambridge Investment Research Advisors
11
Cambridge Investment Research Advisors
Iowa
$27K +$350 +5 +1%
VF
12
Virtu Financial
New York
$23K -$10.4K -148 -27%
Rockefeller Capital Management
13
Rockefeller Capital Management
New York
$23K – – –
SWM
14
SeaCrest Wealth Management
New York
$23K – – –
RJFSA
15
Raymond James Financial Services Advisors
Florida
$22K -$350 -5 -1%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$17K +$6.93K +99 +52%
Millennium Management
17
Millennium Management
New York
$17K +$20.6K +294 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$15K – – –
CAPTRUST Financial Advisors
19
CAPTRUST Financial Advisors
North Carolina
$12K – – –
FWM
20
ForthRight Wealth Management
Georgia
$12K – – –
LPL Financial
21
LPL Financial
California
$9K – – –
CB
22
Community Bank
New York
$8K – – –
SFG
23
SNS Financial Group
Minnesota
$6K – – –
TCM
24
Traynor Capital Management
Pennsylvania
$6K – – –
UBS Group
25
UBS Group
Switzerland
$4K +$560 +8 +15%
1
2

AIM Hedge Fund Activity: Q3 2022 in Review

34 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2022, worth a combined $3.36M — down 28% from $4.68M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AIM and 2 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $20.6K. The largest seller was Morgan Stanley, cutting an estimated $141K.

  • 34 institutional investors held AIM ImmunoTech (AIM) as of Q3 2022, down from 36 in Q2 2022.
  • Funds reported $3.36M of AIM ImmunoTech stock for Q3 2022, down 28% quarter-over-quarter.
  • 2 funds opened new AIM ImmunoTech positions in Q3 2022 and 3 closed out, a net change of -1 holder.
  • The largest AIM ImmunoTech buyer in Q3 2022 was Millennium Management, an estimated $20.6K added.
  • The largest AIM ImmunoTech seller in Q3 2022 was Morgan Stanley, an estimated $141K sold.

Based on aggregated 13F filings for Q3 2022.